WallStSmart
CLDI

Calidi Biotherapeutics Inc.

AMEX: CLDI · HEALTHCARE · BIOTECHNOLOGY

$0.19
-2.87% today

Updated 2026-06-05

Market cap
$3.20M
P/E ratio
P/S ratio
50.83x
EPS (TTM)
$-4.17
Dividend yield
52W range
$0 – $13
Volume
5.6M

Calidi Biotherapeutics Inc. (CLDI) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-143.0%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
-240.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-0.7%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-0.7%
2025-11-13
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-11-13$-2.21-952.4%$1.51$1.50-0.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-09-30$-0.21$-2.21-952.4%
2025-06-30$-0.21$-1.99-847.6%
2025-03-31$-0.25$-0.18+28.0%
2024-12-31$-0.09$-0.27-200.0%$1.50M
2024-09-30$-0.19$-0.65-242.1%
2024-06-30$-0.19$-1.40-636.8%
2024-03-31$-0.28$-0.20+28.6%
2023-12-31$-0.20$-0.48-140.0%
2023-09-30$-0.17$-0.14+17.6%
2023-06-30$-0.43
2023-03-31$-27.02
2022-12-31$0.00$-0.26

Frequently asked questions

Has Calidi Biotherapeutics Inc. beaten earnings estimates?

Calidi Biotherapeutics Inc. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, averaging a -143.0% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.

How does CLDI stock react to earnings?

CLDI has moved an average of -0.7% the day after earnings over its last 1 reports, finishing higher after 0 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.